Evaluating Meaningful Changes in Patient‐Reported Outcome Measurement Information System–Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Patients With Rheumatoid Arthritis
Substantial proportions of patients with RA who received sarilumab reported meaningful change in fatigue measured by PROMIS-Fatigue 10a over time. This study demonstrates the ability to convert FACIT-Fatigue score onto the PROMIS T score metric, the rapid reduction in fatigue with biologic therapies, and the use of novel eCDF curves to show individual patient-level change.
Authors
- Stefano Fiore (ORCID: https://orcid.org/0000-0002-3785-2448)
- Emily Molina (ORCID: https://orcid.org/0000-0002-1576-4850)
- Amy Praestgaard
- David F Cella (ORCID: https://orcid.org/0000-0002-9881-4541)
- Clifton O. Bingham (ORCID: https://orcid.org/0000-0002-4752-5029)
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- AVEO Oncology (United States) (US)
- Sanofi (United States) (US)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1002/acr2.11763
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals